https://romidepsininhibitor.co....m/pedotpss-nano-part
It isn't understood how activating ESR1 mutations may alter the predictive values of molecular imaging representatives for endocrine treatment reaction. This study investigated the result of an activating ESR1 mutation on pre-treatment 18F-fluoroestradiol (18F-FES) uptake and very early assessment of endocrine therapy response making use of 18F-FDG and 18F-fluorofuranylnorprogesterone (18F-FFNP) PET/CT imaging of tumor sugar k-calorie burning and progesterone receptor (PR)
Like
Comment
Share
